Sažetak
Uvod/Cilj. Retke bolesti predstavljaju hronična degenerativna stanja koja mogu dovesti do trajne onesposobljenosti. Cilj ovog rada bio je procena znanja i stavova studenata treće i šeste godine medicine o lečenju retkih bolesti u Srbiji. Metode. U studiji preseka, dve grupe studenata ispunile su upitnik napravljen za potrebe ovog istraživanja: 350/446 (78,48%) studenata treće godine i 242/517 (46,81%) studenata šeste godine. Rezultati. Studenti šeste godine procenili su stepen svoje informisanosti o retkim bolestima kao bolji u odnosu na studente treće godine (medijana 4 i 3, interkvartilni opseg 3–5 i 1–4; p < 0,05). Međutim, značajan procenat učesnika netačno je procenio prevalenciju retkih bolesti definisanu prema standardima Evropske unije (treća godina – 42,68%, šesta – 49,55%). Obavezni predmeti bili su glavni izvor informacija o retkim bolestima (treća godina – 63,14%, šesta – 92,14%). Svi učesnici istraživanja bili su jedinstveni u stavu da su najvažniji problemi obolelih: visoke cene lekova, nedostupnost terapije i nedovoljna informisanost javnosti. Svi studenti bili su saglasni u stavu da društvo treba da poboljša dostupnost terapije za retke bolesti (medijana 10, interkvartilni opseg 8–10, p < 0,05). U cilju unapređenja farmakoterapije retkih bolesti u našoj zemlji, učesnici su predložili formiranje nacionalne strategije za retke bolesti, registrovanje većeg broja lekova, pojednostavljivanje procesa nabavke lekova i ubrzavanje dijagnostičkih procedura. Zaključak. Neophodno je unaprediti znanje i stavove studenata medicine o farmakoterapiji retkih bolesti.
Ključne reči
||retke bolesti
students
medical||
||studenti medicine
education||
||obrazovanje
serbia||
||srbija
Reference
Rare Diseases Europe (EURORDIS). 2013. About rare dis-eases. Available from: http://www.eurordis.rs/ about-rare-diseases. [accessed 2014 July 10].
Krajnovic D. Ethical and social aspects on rare diseases. Filo-zofija i društvo 2012; 23(4): 32−48.
Serbian National Organization for Rare Diseases: About rare diseases. Available from: http://www.norbs.rs/norbs-o-retkim-bolestima.php. [accessed 2014 July 10]. (Serbian)
Byrne PC. Training medical students on rare disorders. Or-phanet J Rare Dis 2012, 7(Suppl 2): A15.
Giehl J, Graessner H, Riess O. First German Academy for Further Medical Training on Rare Diseases (FAKSE, http://www.fakse.info). Orphanet J Rare Dis 2012, 7 (Suppl 2): A41.
Fasser C, von Gizycki R. EC consultation paper: „Rare diseases: Europe’s challenges“. Available from : http://ec.europa.eu/health/archive/ph_threats/non_com/docs/r161_en.pdf. [accessed 2014 June 25].
Rulebook on the List of Drugs Covered by Health Insurance. Official Gazette of the Republic of Serbia No.1/2012. (Ser-bian)
Ten years of orphan medicines legislation in Europe – Euro-pean Medicines Agency reviews success and looks ahead. Available from:
http://www.ema.europa.eu/pdfs/general/direct/pr/29156010en.pdf . [accessed 2014 June 12].
Gericke CA , Riesberg A, Busse R. Ethical issues in funding or-phan drug research and development. J Med Ethics 2005; 31(3): 164−8.
International Ethical Guidelines for Biomedical Research In-volving Human Subjects,CIOMS . http://www.cioms.ch/publications/layout_guide2002.pdf. [accessed 2014 May 23].
Prostran M, Todorović Z, Stojanović R, Potpara T, Nešić Z, Lazić J, et al. Bioethics in clinical trials: vulnerable subjects. In: Todorović Z, Prostran M, Turza K, editors. Bioethics and Pharmacology: Ethics in Preclinical and Clinical Drug Development,. 1st ed. Kerala, India: Transworld Research Network; 2012. p. P87−100.
Todorović Z, Prostran M, Medić B, Vučinić M. Bioethics and pharmacology. In: Todorović Z, Prostran M, Turza K, editors. Bioethics and Pharmacology: Ethics in Preclinical and Clinical Drug Development. 1st ed. Kerala, India: Transworld Re-search Network; 2012. p. P7−13.
National Institute for Clinical Excellence. NHS should consider paying premium prices for drugs to treat patients with very rare diseases says NICE Citizen's Council. London: NICE; 2005.
The National Alliance for people with rare diseases & all who support them. Improving Lives, optimising resources: A vision for the UK Rare Diseases Strategy. 2013. Available from: http://www.raredisease.org.uk/documents/RD-UK-Strategy-Report.pdf. [accessed 2014 May 14].
Beleva E, Yordanova R, Arizankoski D, Pete M, Haralampiev E, Stefanov R. Awareness about rare diseases among medical students in Bulgaria-preliminary results. Available from: http://conf2009.raredis.org/posters/Poster%2077%20-20Ralitsa%20Yordanova.pdf. [accessed 2014 June 1].
Miteva TS, Jordanova R, Iskrov G, Stefanov R. General knowledge and awareness on rare diseases among general practitioners in Bulgaria. Georgian Med News 2011; 193: 16−9.
Taylor CM, Karet Frankl FE. Developing a strategy for the management of rare diseases. BMJ 2012; 344: e2417.
Rare Diseases Europe (EURORDIS). 2013. Europlan project. Available from: http://www.eurordis.org/the-europlan-project. [accessed 2014 June 15].